SenesTech (NASDAQ:SNES) posted its quarterly earnings data on Tuesday. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01, Bloomberg Earnings reports. SenesTech had a negative net margin of 3,908.08% and a negative return on equity of 186.65%.
NASDAQ SNES opened at $1.41 on Wednesday. The stock has a 50 day moving average of $1.50. The company has a quick ratio of 2.76, a current ratio of 3.83 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $38.72 million, a price-to-earnings ratio of -2.23 and a beta of 1.76. SenesTech has a 52-week low of $0.55 and a 52-week high of $1.95.
Separately, ValuEngine raised shares of SenesTech from a “hold” rating to a “buy” rating in a research report on Friday, June 28th.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of SenesTech in the second quarter worth approximately $115,000. Bank of New York Mellon Corp purchased a new stake in shares of SenesTech in the second quarter worth approximately $62,000. MRA Associates USA LLC purchased a new stake in shares of SenesTech in the second quarter worth approximately $46,000. First Interstate Bank purchased a new stake in shares of SenesTech in the second quarter worth approximately $31,000. Finally, Meitav Dash Investments Ltd. purchased a new stake in shares of SenesTech in the first quarter worth approximately $81,000. 6.93% of the stock is owned by institutional investors and hedge funds.
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.